



Extraordinary Together



May 24, 2021

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai 400 001

BSE Scrip Code Equity: 505537
Preference: 717503

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE Symbol: ZEEL EQ
: ZEEL P2

Dear Sirs,

Sub: Newspaper Publication pertaining to Financial Results for the quarter and year ended March 31, 2021

Pursuant to Regulation 47(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement published on May 21, 2021 in Business Standard and Navshakti with respect to Financial Results for the quarter and year ended March 31, 2021.

Request you to take the same on record and acknowledge receipt.

Thanking you,

Yours faithfully,
For Zee Entertainment Enterprises Limited

Ashish Agarwal
Chief Compliance Officer & Company Secretary
Membership No F6669

Encl: As above

Zee Entertainment Enterprises Limited

Regd. Office : 18th Floor, A-Wing, Marathon Futurex, N.M. Joshi Marg, Lower Parel, Mumbai - 400 013, India
P. +91 22 7106 1234 | F. +91 22 2300 2107 | CIN : L92132MH1982PLC028767 | www.zee.com

NOTICE OF PROXY ENTRUSTMENT - 2021 ASHAPURA INFRATEX FIBREON LIMITED IN LIQUIDATION					
Lloyd's Metals and Energy Limited					
<p>NOTICE: Notice given under Section 19(2)(b) of the Securities Contracts (Regulation) Act, 1956 ("SCRA"), (hereinafter referred to as "the Company") in respect of the Annual General Meeting ("AGM") of the Company to be held at the registered office of the Company at "1000 DLF Phase II, Sector 151, Phase 2, Sector 150, Noida-201301" on 27th June, 2021 (Friday) at 11:00 AM (India Standard Time). In view of the COVID-19 Pandemic, the AGM will be held by video conferencing.</p> <p>The Company has been declared insolvent by the Noida District Court on 19th August, 2020 vide its Order No. 2020/20/CL/151/308 dated 19th August, 2020. The Company has been put into liquidation. The AGM will be held in accordance with the provisions of the Insolvency and Bankruptcy Code, 2016 ("IBC") and the rules made thereunder and the rules of the stock exchange.</p> <p>The notice is given for the Annual General Meeting ("AGM") of the Company to be held at the registered office of the Company on 27th June, 2021 (Friday) at 11:00 AM (India Standard Time).</p>					
<p>For and on behalf of the Board of Directors Place: Noida Date: 20 May, 2021 Identified as Authorised Signatory: Lekha Shinde</p>					
<p>NOTICE OF PROXY ENTRUSTMENT - 2021 ASHAPURA INFRATEX FIBREON LIMITED IN LIQUIDATION</p>					
<p>Lloyd's Metals and Energy Limited</p>					
<p>NOTICE: Notice given under Section 19(2)(b) of the Securities Contracts (Regulation) Act, 1956 ("SCRA"), (hereinafter referred to as "the Company") in respect of the Annual General Meeting ("AGM") of the Company to be held at the registered office of the Company at "1000 DLF Phase II, Sector 151, Phase 2, Sector 150, Noida-201301" on 27th June, 2021 (Friday) at 11:00 AM (India Standard Time). In view of the COVID-19 Pandemic, the AGM will be held by video conferencing.</p> <p>The Company has been declared insolvent by the Noida District Court on 19th August, 2020 vide its Order No. 2020/20/CL/151/308 dated 19th August, 2020. The Company has been put into liquidation. The AGM will be held in accordance with the provisions of the Insolvency and Bankruptcy Code, 2016 ("IBC") and the rules made thereunder and the rules of the stock exchange.</p> <p>The notice is given for the Annual General Meeting ("AGM") of the Company to be held at the registered office of the Company on 27th June, 2021 (Friday) at 11:00 AM (India Standard Time).</p>					
<p>For and on behalf of the Board of Directors Place: Noida Date: 20 May, 2021 Identified as Authorised Signatory: Lekha Shinde</p>					
<p>NOTICE OF PROXY ENTRUSTMENT - 2021 Balaxi Pharmaceuticals Limited</p>					
<p>NOTICE: Notice given under Regulation 45 of the Union Bank of India Circular Letter No. 1203 dated 23/05/2018 ("Circular Letter") issued by the Reserve Bank of India ("RBI") dated 21/03/2018 (Circular Letter) in respect of the Extraordinary General Meeting ("EGM") of the Shareholders of Balaxi Pharmaceuticals Limited ("Company") to be held at the registered office of the Company at "Plot No. 104, Sector 12, Faridabad, Haryana - 121001" on 27th May, 2021 from 09:00 AM to 10:00 AM (India Standard Time).</p> <p>The Company may be declared bankrupt or insolvent, accordingly, shareholders may refer to section 8(2) of the Bankruptcy Code, 2016 ("Bankruptcy Code") if the Company fails to pay its debts in time as per the Circular Letter. In case of insolvency, shareholders may refer to section 8(2) of the Insolvency and Bankruptcy Code, 2016 ("IBC").</p> <p>The Circular Letter states that the shareholders may exercise their voting rights in accordance with the provisions of the Circular Letter. The shareholders have the absolute right to decide at least one of all or, if necessary, two or more issues to be discussed at the meeting, including the resolution to approve or refuse any scheme of arrangement or amalgamation.</p> <p>For and on behalf of the Board of Directors Place: Hyderabad Date: 20th May, 2021 Identified as Authorised Signatory: Anil Kumar</p>					
<p>EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2021</p>					
<p>STANDALONE CONSOLIDATED</p>					
No.	Particulars	Quarter ended 31st March, 2021 Year ended 31st March, 2021	Quarter ended 31st March, 2021 Year ended 31st March, 2020	Quarter ended 31st March, 2021 Year ended 31st March, 2020	Quarter ended 31st March, 2021 Year ended 31st March, 2020
1.	Total Income from Operations*	2,079.77	1,867.12	2,770.84	2,272.52
2.	Profit/(Loss) for the period starting before Tax, Exceptional and/or Extraordinary items	-450.32	2,088.47	277.28	2,608.21
3.	Net profit/(loss) for the period starting before Tax, Exceptional and/or Extraordinary items	-450.32	2,088.47	277.28	2,608.21
4.	Total Profit/(Loss) for the period starting after Tax, Exceptional and/or Extraordinary items	-450.32	2,088.47	277.28	2,608.21
5.	Total Comprehensive income for the period starting before Tax, Exceptional and/or Extraordinary items, other than profit/(loss)	2,025.46	1,511.34	144.00	940.99
6.	Equity items equity	-1,280.00	1,000.00	4,000.00	1,000.00
7.	Difference in fair value of non-controlling interest due to changes in shareholding interest of non-controlling interest	79.04	79.04	79.04	79.04
8.	Basic (excluding effects of dilution)	8.15	10.12	1.00	9.04
	(In Lakh, unless specified)	2,025.46	1,511.34	144.00	940.99

*Includes other income. **Includes preference股息。

Note: 1. The above is an extract of the audited Standalone and Consolidated Financial Results of the Company as per the Stock Exchange requirements.

2. This statement has been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

For and on behalf of the Board of Directors,
Balaxi Pharmaceuticals Limited
Anil Kumar
Managing Director

ZEE ENTERTAINMENT ENTERPRISES LIMITED								
CIN: L92132MH1982PLC028767 Regd. Office: 18 th Floor, A' Wing, Maratha Futurex, N.M.Joshi Marg, Lower Parel, Mumbai-400013 Tel: +91-22-7106 1234 Fax: +91-22-3303 2107 Website: www.zee.com Financial Results for the quarter and year ended 31 March 2021								
No.	Particulars	Quarter ended 31st March, 2021 Year ended 31st March, 2020	Interim Quarter ended 31st March, 2021 Year ended 31st March, 2020	Year ended 31st March, 2021 Audited Audited Audited	Year ended 31st March, 2020 Audited Audited Audited	Quarter ended 31st March, 2021 Year ended 31st March, 2020	Quarter ended 31st March, 2021 Year ended 31st March, 2020	Year ended 31st March, 2021 Audited Audited Audited
1.	Total income from operations*	162,063	173,554	866,535	725,301	195,582	195,108	772,992
2.	Profit/(Loss) for the period starting before Tax, Exceptional and/or Extraordinary items	54,480	(14,520)	149,888	149,778	48,334	(10,533)	130,231
3.	Profit/(Loss) for the period starting before Tax, Exceptional and/or Extraordinary items	87,325	(25,490)	198,222	121,304	43,860	(60,320)	124,061
4.	Profit/(Loss) for the period starting after Tax, (after Exceptional and/or Extraordinary items)	43,742	(30,065)	112,374	79,190	27,306	(78,682)	125,567
5.	Total Comprehensive income for the period starting before Tax, (after Exceptional and/or Extraordinary items)	43,742	(30,065)	112,374	79,190	27,306	(78,682)	125,567
6.	Equity Share Capital	43,572	(28,400)	112,138	78,036	27,480	(80,919)	77,704
7.	Other equity (including revaluation reserves)	9,505	8,625	9,626	9,805	5,406	8,805	6,856
8.	Reserves**			385,157	753,185			504,501
9.	Outstanding preference shares (Face Value)			913,005	822,303			991,845
10.	Earnings per Share (in Rs. 1/- each) (not continuing operations)			40,359	80,578			1,047,773
11.	Basic (Rs.) (not Annualized)			4.58	(1.13)	11.67	7.82	8.33
12.	Net Debt (Rs.) (not Annualized)			4.58	(1.13)	11.67	7.82	8.33

*Includes other income. ** Includes preference股息

Note: 1. The above is an extract of the detailed format of Financial Results filed by the Company with the Stock Exchange under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results is available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and also on Company's website at www.zee.com.

2. This financial statement has been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

For and on behalf of the Board
Paul Gaitka
Managing Director & CEO

